COVID-19 in patients with thoracic malignancies (TERAVOLT): first results of an international, registry-based, cohort study

Early reports on patients with cancer and COVID-19 have suggested a high mortality rate compared with the general population. Patients with thoracic malignancies are thought to be particularly susceptible to COVID-19 given their older age, smoking habits, and pre-existing cardiopulmonary comorbidities, in addition to cancer treatments. We aimed to study the effect of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection on patients with thoracic malignancies.

The Lancet Oncology 2020 Non-Small Cell Lung Cancer